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Cyclooxygenase-2 (COX-2) enzyme is upregulated in
oral cancer (OSCC), where it catalyses PGE2 synthesis.
We have shown previously that PGE2 promotes integ-
rin-dependent OSCC invasion (1). PGE2 has four recep-
tors (EP1-4), each coupled to different intracellular
signaling pathways. We therefore investigated the role of
EP receptor signaling in the invasive process.
We used immunochemistry and RT-PCR to examine
EP receptor expression in OSCC cell lines and OSCC
in vivo, and found marked upregulation of EP4. Chemical
inhibition or transient knockdown of EP4 in OSCC lines
significantly reduced levels of intracellular cyclic AMP
(cAMPi), whereas EP4 overexpression increased cAMPi.
Using Transwell and organotypic invasion assays, we stu-
died the functional role of EP4. Overexpression of EP4
promoted OSCC invasion, with confocal microscopy
revealing that EP4 localized to filopodia, processes asso-
ciated with cell motility. Conversely, inhibition of either
EP4 or cAMPi suppressed invasion. Treatment of cells
with the cAMP agonist, forskolin, restored invasion fol-
lowing PGE2 suppression. We identified the GTP-ase,
Rac1, as a downstream target of cAMPi, where inhibition
of EP4 or cAMPi suppressed Rac1 activation, and RNAi
abrogation of Rac1 inhibited invasion.
Our data describe a novel signaling pathway in cancer
invasion, and suggest that COX-2/PGE2-dependent
OSCC signaling is primarily modulated through the EP4
receptor, leading to increased cAMPi and Rac1 activa-
tion. Targeting EP4 may be an important strategy to
suppress tumor progression, and may avoid the side-
effects associated with systemic administration of
COX-2 inhibitors.
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